New combo therapy aims to boost immune attack on melanoma before surgery
NCT ID NCT03769155
First seen May 05, 2026 · Last updated May 05, 2026
Summary
This early-stage study tests whether adding an experimental drug (VX15/2503) to standard immunotherapies (ipilimumab or nivolumab) can help the immune system fight advanced melanoma that can be surgically removed. About 41 adults with stage IIIB-D melanoma will receive the drug combination before surgery. Researchers will measure immune cell activity in tumors and monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATHOLOGIC STAGE IIIB CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Conditions
Explore the condition pages connected to this study.